Kamada Announces Collaboration Agreement With Yissum For Development Of A Recombinant Human Alpha 1 Antitrypsin

NESS ZIONA, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA) a plasma-derived protein therapeutics company focused on orphan indications, announced today that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT).  The goal of this development work is to maximize protein yields and functionality.  

The collaboration will be led by Dr. Tsafi Danieli, Head of the Protein Expression Facility at Hebrew University.  Dr. Danieli has a vast amount of experience in recombinant DNA technologies and protein production systems.

"We are pleased to be working with the Hebrew University on the development of a recombinant human Alpha 1 Antitrypsin, as they are experts in recombinant DNA technologies and protein production systems," said Amir London, Kamada's Chief Executive Officer.  "We initiated our development activities in the rhAAT field several years ago in preparation for future increased demand for AAT resulting from greater awareness of AAT deficiency, as well as potential additional indications for Alpha 1 Antitrypsin, which are currently in clinical development. Upon completion of the current work with Yissum, we intend to begin GMP-manufacturing scale up activities.  Our collaboration with Yissum is intended to maintain our innovative global leadership in the area of AAT development in multiple indications."   

"The development of an effective recombinant human Alpha 1 Antitrypsin is an important undertaking and would address a significant unmet therapeutic development need," said Yaacov Michlin, President and CEO of Yissum.  "We are excited to collaborate with Kamada on this key project, as our work will result in expanding the range of new technologies and analytical methods essential for the development of therapeutic proteins."

Kamada has previously developed analytical methods (physicochemical, biochemical, in-vitro, and in-vivo) that will help identify and characterize functional rhAAT.  In addition, the Company has established a significant understanding of a favorable expression system and growth conditions required to successfully develop an effective rhAAT.

If you liked this article you might like

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

3 Stocks Pushing The Drugs Industry Lower

Can Billionaire John Paulson Bounce Back With Health Care?